[Comparative characteristics of vanadium-containing compounds, possessing insulin-like effects]
M A Golubev1, V K Gorodetskiĭ, A P Anis'kina
1Institute of Biomedical Chemistry RAMS, Moscow, Russia.
Voprosy Meditsinskoi Khimii
|July 8, 2000
Summary
Vanadium compounds like orthovanadate and vanadyl sulfate improve diabetes markers in rats. Vanadyl sulfate showed stronger insulin-mimetic effects and lower toxicity compared to orthovanadate.
Area of Science:
- Biochemistry
- Pharmacology
- Toxicology
Background:
- Diabetes mellitus is a metabolic disorder characterized by hyperglycemia.
- Vanadium compounds have shown potential insulin-mimetic properties.
- Streptozotocin-induced diabetes in rats is a common model for studying diabetes treatments.
Purpose of the Study:
- To evaluate the long-term effects of orthovanadate and vanadyl sulfate on diabetic rats.
- To compare the efficacy and toxicity of these two vanadium compounds.
Main Methods:
- Streptozotocin-induced diabetic rats were treated with oral orthovanadate and vanadyl sulfate.
- Serum glucose, HbA1c, fructoseamine, liver enzymes (AST, ALT), amylase, and hepatic glycogen and glucokinase activity were measured.
- LD-50 and cytotoxicity assays were performed on isolated hepatocytes.
Main Results:
- Both orthovanadate and vanadyl sulfate improved key diabetes parameters.
- Vanadyl sulfate exhibited more pronounced insulin-mimetic properties than orthovanadate.
- Vanadyl sulfate demonstrated lower toxicity in cytotoxicity and LD-50 analyses compared to orthovanadate.
Conclusions:
- Orthovanadate and vanadyl sulfate show therapeutic potential for diabetes.
- Vanadyl sulfate is a more effective and safer vanadium-based treatment option for diabetes compared to orthovanadate.
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...